X4 Pharmaceuticals
XFOR
56 hedge funds and large institutions have $53.6M invested in X4 Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 16 increasing their positions, 9 reducing their positions, and 8 closing their positions.
78% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 9
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
8% more funds holding
Funds holding: 52 → 56 (+4)
0.01% more ownership
Funds ownership: 1.66% → 1.68% (+0.01%)
11% less capital invested
Capital invested by funds: $60.1M → $53.6M (-$6.54M)
68% less call options, than puts
Call options by funds: $49K | Put options by funds: $151K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$4.44M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$747K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$509K |
| 4 |
JP Morgan Chase
New York
|
+$495K |
| 5 |
SM
Scoggin Management
New York
|
+$474K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$2.37M |
| 2 |
SCM
Sio Capital Management
New York
|
-$1.81M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$1.34M |
| 4 |
LCM
Lynwood Capital Management
Toronto,
Ontario, Canada
|
-$1.23M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$906K |
XFOR Hedge Fund Activity: Q1 2023 in Review
56 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q1 2023, worth a combined $53.6M — down 11% from $60.1M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new XFOR positions and 8 closed out — a net gain of 4 holders — while 16 added to existing stakes and 9 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $4.44M. The largest seller was CVI Holdings, exiting entirely with an estimated $2.37M sold.
- 56 institutional investors held X4 Pharmaceuticals (XFOR) as of Q1 2023, up from 52 in Q4 2022.
- Funds reported $53.6M of X4 Pharmaceuticals stock for Q1 2023, down 11% quarter-over-quarter.
- 12 funds opened new X4 Pharmaceuticals positions in Q1 2023 and 8 closed out, a net change of +4 holders.
- The largest X4 Pharmaceuticals buyer in Q1 2023 was Perceptive Advisors, an estimated $4.44M added.
- The largest X4 Pharmaceuticals seller in Q1 2023 was CVI Holdings, an estimated $2.37M sold.
Based on aggregated 13F filings for Q1 2023.